Good morning, myeloma world.

We hope you had a pleasant weekend and that your new week is off to a good start.

The big news today is that Darzalex (daratumumab) has been approved in Europe as a new treatment for multiple myeloma. We will be pub­lish­ing a separate news article on the approval, which was announced a few hours ago. In the mean­time, you can find information about the approval in this press release from Genmab, the company that initially developed Darzalex.

The other news we have for you …

Good morning, myeloma world.

It's Monday, and the weekend definitely is over. The vigorous activity in our email inbox is making that eminently clear. But, with the week still so young, there isn't much new myeloma research for us to review with you. In fact, we have just two new studies that we'd like to discuss today.

Both studies are by European researchers who have compiled and analyzed retrospective data on some important topics.

One study out of Portugal looks at the use of Revlimid (lenalidomide) to treat multiple myeloma patients who …